SAN DIEGO, May 13, 2024 /PRNewswire/ -- ChemDiv, Inc, announced today that Bill Farley, CEO, will participate in the EF Hutton Annual Global Conference (https://efhutton.com/conference/). The conference is being held in person at The Plaza Hotel, NY, NY 10019 on May 15, 2024.
ChemDiv Marks a Milestone as Orionis' Novel Immunotherapy Enters Ph I Trials
SAN DIEGO, Dec. 19, 2023 /PRNewswire/ -- ChemDiv Inc., dedicated to partnering in discovery and development of breakthrough therapies based on its unique chem-bio platforms, announces successful completion of Phase I clinical trials for AV5124, an innovative influenza virus replication inhibitor being developed by Viriom Inc. (Viriom).
SAN DIEGO, Dec. 13, 2023 /PRNewswire/ -- ChemDiv Inc., dedicated to partnering in discovery and development of breakthrough therapies based on its unique chem-bio platforms, announces the presentation of non-clinical summary data for the best-in-class selective BCL2 inhibitor clinical candidate at the 65th ASH Annual Meeting and Exposition in San Diego, CA.
SAN DIEGO, Oct. 25, 2023 /PRNewswire/ -- ChemDiv, a leading global contract research organization (CRO), is excited to announce the expansion of its Business Development Team with the addition of two seasoned professionals, Peter Dmitriev as Business Development Manager and David Stark as Senior Regional Director of Business Development. In conjunction with this talent acquisition, ChemDiv is also pleased to announce relocation to expanded San Diego headquarters, which will enable our growing scientific and technical teams to collaborate more effectively, thereby enhancing our capabilities to serve as a premier solutions partner to our Pharma and biotech customers.